Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Ularitide has been registered.
- 5 registered studies in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 5 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 2,241 people took part in those.
How far along it is
- 1 trial has reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 2 have published results in the medical literature that anyone can read.
- The research spans 23 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 5 of 5 trials for Ularitide.
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
University of Aarhus
Cirrhosis, Liver · Ascites Hepatic
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
Cardiorentis
Acute Decompensated Heart Failure
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
Rocky Mountain Cancer Centers
Renal Dysfunction · Acute Renal Failure · Mortality
The natriuretic and diuretic effects of urodilatin in cirrhosis patients with severe sodium retention
Aarhus University Hospital (Denmark)
Decompensated liver cirrhosis.
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
Facet Biotech
Heart Failure, Congestive
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Ularitide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.